Nexcon Pharmatechs

Nexcon Pharmatechs is a biopharmaceutical company focused on the discovery and development of innovative small molecule drugs, with a particular emphasis on Targeted Protein Degradation (TPD) technologies. The company utilizes its proprietary Nex-Degradation platform to design and optimize Proteolysis-Targeting Chimeras (PROTACs) for the treatment of cancer and other serious diseases. Their pipeline includes programs targeting the androgen receptor for prostate cancer and the estrogen receptor for breast cancer, as well as novel targets like BCL6 and STAT3. Nexcon Pharmatechs aims to address unmet medical needs by overcoming drug resistance associated with traditional inhibitors through the complete removal of disease-causing proteins.